Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 2,204 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control I Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects

NCT01818011
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322 Initial fit for purpose tablets, GSK1322322 over granulated tablets, GSK1322322 intended commercial tablets, Placebo tablets, 13C-GSK1322322 stable isotope powder, GSK1322322 for injection, Placebo injection
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 22, 2026, 12:15 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Preeclampsia Research on Vitamin D, Inflammation, & Depression

NCT03018132
View directory record Official record
Conditions
Pre-Eclampsia, Depression, Inflammation, Vitamin D Deficiency
Interventions
mental health screening, education and referral program
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 12:15 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

NCT06069544
View directory record Official record
Conditions
Malaria
Interventions
BNT165c, BNT165d, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
5
States / cities
Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 22, 2026, 12:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

NCT05581641
View directory record Official record
Conditions
Malaria
Interventions
BNT165b1, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
5
States / cities
Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 22, 2026, 12:15 PM EDT
Withdrawn Not applicable Interventional

Pilot Study of the Effects of Circadian Rhythms on the Treatment of Bipolar I Depression.

NCT00726154
View directory record Official record
Conditions
Bipolar Disorder
Interventions
IPSRT, Collaborative Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 22, 2026, 12:15 PM EDT
Not listed Not applicable Interventional

Acceptability/Feasibility of IU Intervention

NCT05172427
View directory record Official record
Conditions
Generalized Anxiety Disorder, Emotional Disorder
Interventions
14 days of EMI, Uncertainty reappraisal training
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 22, 2026, 12:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

NCT01406418
View directory record Official record
Conditions
Influenza
Interventions
CR6261 2 mg/kg, CR6261 5 mg/kg, CR6261 15 mg/kg, CR6261 30 mg/kg, CR6261 50 mg/kg, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 22, 2026, 12:15 PM EDT
Completed Phase 4 Interventional

Study to Determine Whether Ramelteon Helps People With REM Sleep Behavior Disorder

NCT01401413
View directory record Official record
Conditions
REM Sleep Behavior Disorder
Interventions
ramelteon, placebo
Drug
Lead sponsor
Sleep Medicine Centers of WNY
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
West Seneca, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 22, 2026, 12:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

NCT04660890
View directory record Official record
Conditions
Healthy
Interventions
ALXN2050, ALXN2050-matching Placebo, Moxifloxacin, Moxifloxacin-matching Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 22, 2026, 12:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects

NCT05085197
View directory record Official record
Conditions
Healthy
Interventions
STSA-1005 injection, Placebo
Drug
Lead sponsor
Staidson Biopharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 22, 2026, 12:15 PM EDT
Completed Phase 3 Interventional Results available

12 / 48 Week Pivotal PFT vs PBO in COPD I

NCT00782210
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Olodaterol (BI1744), placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
21
States / cities
Jasper, Alabama • Berkeley, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 22, 2026, 12:15 PM EDT
Active, not recruiting Phase 3 Interventional

Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta

NCT05768854
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Bisphosphonate, Setrusumab
Drug · Biological
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
2 Years to 6 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 12:15 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

NCT05987423
View directory record Official record
Conditions
Thyroid Eye Disease, TED
Interventions
Satralizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Beverly Hills, California • La Jolla, California • Wichita, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 22, 2026, 12:15 PM EDT
Completed No phase listed Observational

Expressive Writing and Adjustment to Metastatic Breast Cancer

NCT00624156
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Writing Intervention
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2015 · Synced Oct 22, 2026, 12:15 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

NCT05385783
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CYB003, Psychotherapy, Placebo, Psychological Support
Drug · Behavioral
Lead sponsor
Cybin IRL Limited
Industry
Eligibility
21 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 22, 2026, 12:15 PM EDT
Withdrawn No phase listed Observational

Neurodevelopmental Outcome of Early Dietary Lysine Restriction in Pyridoxine Dependent Epilepsy Patients

NCT01795170
View directory record Official record
Conditions
Pyridoxine Dependant Epilepsy
Interventions
Lysine Restricted Diet, Pyridoxine
Dietary Supplement · Drug
Lead sponsor
University of British Columbia
Other
Eligibility
3 Months to 3 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 22, 2026, 12:15 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Community Enhanced Virtual Informed Consent

NCT07805083
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Educational Cancer Intervention, ICF Text Version 1, ICF Text Version 2, ICF Video Version 1, ICF Video Version 2, ICF Video Version 3, ICF Video Version 4, Survey Administration
Behavioral · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 22, 2026, 12:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

NCT04588922
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
SLS009, venetoclax, azacitidine
Drug
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
12 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 22, 2026, 12:15 PM EDT
Completed Not applicable Interventional

Mindfulness Meditation and Insomnia in Alzheimer Disease Caregivers

NCT03538574
View directory record Official record
Conditions
Insomnia Chronic
Interventions
CBT-I, MAP-I
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
45 Years to 95 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 22, 2026, 12:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing Uptake of Preconception Care Services in Family Practice Clinics Using a Patient Centered Screening Tool

NCT06582160
View directory record Official record
Conditions
Women, Reproductive Age
Interventions
Risk-Based Pre-conception Screening, Patient-centered Pre-conception Screening
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 49 Years · Female only
Enrollment
286 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 22, 2026, 12:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults

NCT00382980
View directory record Official record
Conditions
Influenza
Interventions
Aluminum hydroxide, Inactivated Vero cell based whole virus influenza A/H5N1, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
5
States / cities
Stanford, California • Torrance, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 22, 2026, 12:15 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss

NCT00000854
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Nandrolone decanoate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 22, 2026, 12:15 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

NCT01853046
View directory record Official record
Conditions
Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 22, 2026, 12:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC

NCT04476797
View directory record Official record
Conditions
SBRT, NSCLC, Non-metastatic
Interventions
GC4711 +SBRT, Placebo +SBRT
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Greeley, Colorado • Loveland, Colorado • Columbus, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 22, 2026, 12:15 PM EDT